Anavex Life Sciences Corp. $AVXL Shares Sold by Nwam LLC

Nwam LLC reduced its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 14.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 874,283 shares of the biotechnology company’s stock after selling 150,196 shares during the period. Anavex Life Sciences comprises 0.6% of Nwam LLC’s holdings, making the stock its 25th biggest position. Nwam LLC owned about 1.02% of Anavex Life Sciences worth $8,175,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $97,000. Gladstone Institutional Advisory LLC raised its position in Anavex Life Sciences by 19.6% during the third quarter. Gladstone Institutional Advisory LLC now owns 59,529 shares of the biotechnology company’s stock valued at $530,000 after acquiring an additional 9,764 shares in the last quarter. Foster Victor Wealth Advisors LLC boosted its position in Anavex Life Sciences by 7.5% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 40,478 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 2,815 shares in the last quarter. Sheets Smith Investment Management acquired a new stake in shares of Anavex Life Sciences during the 3rd quarter worth approximately $1,210,000. Finally, PVG Asset Management Corp increased its holdings in shares of Anavex Life Sciences by 34.9% during the 2nd quarter. PVG Asset Management Corp now owns 111,445 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 28,837 shares in the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Trading Up 0.6%

NASDAQ:AVXL opened at $4.85 on Friday. The stock has a 50 day moving average of $4.19 and a two-hundred day moving average of $7.81. Anavex Life Sciences Corp. has a 12 month low of $2.86 and a 12 month high of $13.99. The firm has a market cap of $433.35 million, a P/E ratio of -8.98 and a beta of 1.17.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same period last year, the business earned ($0.14) earnings per share. On average, research analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on AVXL. Weiss Ratings restated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, January 6th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Anavex Life Sciences in a research report on Friday, December 19th. Finally, Jones Trading lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $22.00.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.